These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 31899984)

  • 21. New drugs for NAFLD: lessons from basic models to the clinic.
    Reimer KC; Wree A; Roderburg C; Tacke F
    Hepatol Int; 2020 Jan; 14(1):8-23. PubMed ID: 31802390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 23. Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys.
    Thompson KE; Guillot M; Graziano MJ; Mangipudy RS; Chadwick KD
    Toxicol Appl Pharmacol; 2021 Oct; 428():115673. PubMed ID: 34364948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
    Issa D; Wattacheril J; Sanyal AJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis.
    Esteban JPG; Asgharpour A
    Gastroenterol Clin North Am; 2020 Mar; 49(1):105-121. PubMed ID: 32033758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-drug approaches to NASH: what's in the development pipeline?
    Johnston MP; Patel J; Byrne CD
    Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
    [No Abstract]   [Full Text] [Related]  

  • 29. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of tritium labeled 30-KDa PEG and conjugation to form [
    Easter JA; Tian Y; Burrell RC; Hong Y; Bonacorsi SJ
    J Labelled Comp Radiopharm; 2021 Oct; 64(12):477-481. PubMed ID: 34386991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.
    Sanyal AJ; Friedman SL; McCullough AJ; Dimick-Santos L; ;
    Hepatology; 2015 Apr; 61(4):1392-405. PubMed ID: 25557690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges.
    Tian H; Zhang S; Liu Y; Wu Y; Zhang D
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis.
    Qi J; Guo Z; Zhu S; Jiang X; Wu Y; Chen Y; Hu F; Xiong J; Wu Y; Ye X; Liang X
    Int J Biol Macromol; 2024 Mar; 261(Pt 1):129797. PubMed ID: 38290625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
    Tacke F
    Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
    PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
    Cernea S; Cahn A; Raz I
    Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
    Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
    Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
    [No Abstract]   [Full Text] [Related]  

  • 40. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis.
    Iwaki M; Yoneda M; Wada N; Otani T; Kobayashi T; Nogami A; Saito S; Nakajima A
    Expert Opin Emerg Drugs; 2024 Jun; 29(2):127-137. PubMed ID: 38469871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.